

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000640

International filing date: 21 February 2005 (21.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0403773.5  
Filing date: 20 February 2004 (20.02.2004)

Date of receipt at the International Bureau: 21 April 2005 (21.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *William Morell*

Dated 5 April 2005





20 FEB 2004

NEWPORT

The Patent Office

Cardiff Road  
Newport  
South Wales NP10 8QQ

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet, from the Patent Office to help you fill in this form)

1. Your reference CDK2161

2. Patent application number  
(The Patent Office will fill in this part) 20 FEB 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)  
RHODIA CONSUMER SPECIALTIES LIMITED  
Oak House  
Reeds Crescent  
Watford  
Hertfordshire, WD24 4QP  
0403773.5

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation  
England

7870322006

4. Title of the invention EMBEDDED BIOCID

5. Name of your agent (if you have one) Barker Brettell  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)  
138 Hagley Road  
Edgbaston  
Birmingham  
B16 9PW

Patents ADP number (if you know it) 7442494002

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country	Priority application number (if you know it)	Date of Filing (day/month/year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier application	Date of filing (day/month/year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
Otherwise answer NO (See note(d)) YES

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document  
Continuation sheets of this form

Description 8 + 8

Claim(s) 4 + 4

Abstract



Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination YES - 1  
(*Patents Form 9/77*)

Request for substantive examination  
(*Patents Form 10/77*)

Any other documents  
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature

  
Barker Brettell

Date

19/02/2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Lucy P. Trueman

Tel: 0121 456 1364

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

## EMBEDDED BIOCIDES

This invention relates to a phosphonium compound embedded in a matrix substrate, the use of such an embedded phosphonium compound and a method of using an embedded phosphonium compound.

Phosphonium compounds, such as THP (tris (hydroxymethyl) phosphine) and its associated salts, THP sulphate and THP chloride, are effective biocides and scale dissolvers that are widely used in water treatment and oil field applications for the control of micro-organisms and scale. Such micro-organisms include sulphate reducing bacteria, general heterotrophic bacteria and algae. These micro-organisms are responsible for scale formation in aqueous systems found in industry. Typically the scale comprises, iron carbonate or iron, lead and zinc sulphide deposits.

Phosphonium compounds are conventionally supplied as liquid based products, but solid forms of phosphonium compounds are commercially available. Solid forms typically comprise phosphonium compounds coated onto a solid, inert, substrate such as adipic acid.

Liquid based phosphonium compounds react or interfere with the performance of commonly used oxygen scavengers. For example, sulphite based scavengers and erythorbic acid, with the result being that complete deaeration of systems containing liquid based phosphonium compounds is difficult to achieve.

Accordingly, the present invention provides a phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from the group consisting of tris (hydroxyorgano) phosphine (THP), a THP<sup>+</sup> salt (tetrakis (hydroxyorgano) phosphonium salt) or a condensate of THP and a nitrogen containing compound.

The present invention offers the following advantages:-

5           The embedded phosphonium compound can be used for applications that neither conventional liquid or solid forms of the phosphonium compound are suitable for;

10           With the phosphonium compound embedded in a matrix substrate, the resulting product can be dosed into system requiring deaeration, for example, oil field water injection systems and transmission pipelines during hydrostatic testing; without impacting upon the performance of the oxygen scavenger;

15           A delivery system for phosphonium compounds is provided that enables the phosphonium compound to be dosed into systems containing oxygen scavengers without incompatibility problems. This is not currently possible;

20           A delivery system for a phosphonium compound is provided that does not adversely affect the performance of the phosphonium compound or the overall treatment program used in aqueous systems;

25           A delayed release system is provided that allows sustained controlled dissolution of the phosphonium compound into aqueous systems;

30           A delivery system is provided whereby the rates of dissolution of the embedded phosphonium compound can be controlled by the matrix composition;

A delivery system is provided that minimises direct contact with the biocide;

5 A delivery system is provided which is deployable in areas of low expertise and an absence of mechanical equipment, for example, pumps;

10 A delivery system is provided that allows phosphonium compounds to be formulated with other treatment chemicals or enhancers that would normally be incompatible if initially combined with an aqueous solution.

15 Preferably the  $\text{THP}^+$  salt is tetrakis (hydroxymethyl) phosphonium sulphate. Alternatively, the  $\text{THP}^+$  salt is tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium formate, tetrakis (hydroxymethyl) phosphonium acetate or tetrakis (hydroxymethyl) phosphonium oxalate.

20 The nitrogen containing compound is preferably urea. Alternatively, it may be melamine, guanidine or dicyandiamide.

25 The matrix substrate has a melting point of between 5 to 80° C. Preferably the melting point is between 20 to 70°C. More preferably, the melting point is 60°C.

Preferably the matrix substrate is soluble in water at a temperature of between 5 to 100°C, especially 20°C.

30 The matrix substrate is preferably selected from a polyhydric compound. Preferably the polyhydric compound is a polyethylene glycol with a molecular weight of above 600. More preferably, the polyhydric



compound is polyethylene glycol 8000. Alternatively, the matrix substrate is selected from the group consisting of ethoxylated surfactants, fatty alcohols, ethoxylated fatty alcohols, ethoxylated alkyl phenols, ethoxylated fatty acids, fatty acid alkanolamides, ethylene  
5 oxide/propylene oxide block copolymers, ethoxylated/propoxylated fatty alcohols, polyethylene glycol esters, glycol esters, alkyl benzene sulphonic acids and salts thereof.

The matrix substrate may be a mixture of two or more of the compounds  
10 selected above.

The present invention also provides in a second aspect the use of a phosphonium compound as defined in the first aspect.

15 Preferably, the phosphonium compound is used to reduce the numbers of micro-organisms in industrial systems. Alternatively, the phosphonium compound is used to reduce iron carbonate or iron, lead and zinc scale deposits.

20 The industrial system is selected from the group consisting of storage vessels for water and fuel; fuel and gas pipelines; gas lift wells; water injection systems; oil or gas production wells; cooling tower aqueous systems; aqueous systems in paper production and the like and any other aqueous system where micro-organism contamination is a problem.

25

Preferably the micro-organism is selected from the group consisting of sulphate reducing bacteria, general heterotrophic bacteria and algae.

According to a third aspect, the present invention provides a method for  
30 reducing the numbers of micro-organisms in an industrial system which method comprises the step of contacting the industrial system with an

effective amount of a phosphonium compound as defined in the first aspect of the invention to reduce the number of micro-organisms.

5 According to a fourth aspect, the present invention provides a method for reducing the amount of scale in an industrial system which method comprises the step of contacting the industrial system with an effective amount of a phosphonium compound as defined in the first aspect of the invention to reduce the amount of scale.

10 The phosphonium compound according to the first aspect may be formulated with one or more of the following: scale inhibitors, corrosion inhibitors, additional biocides, demulsifiers, gas hydrate inhibitors, asphaltene inhibitors/dispersants, other surfactants, anti-foams/defoamers, fragrances, wax inhibitors, scale solvers, gelling agents, oxygen  
15 scavengers.

The embedded biocide in accordance with the invention may be in the form of sticks/candles, beads, pellets, bricks, shavings, flakes or prills and the like.

20

An embodiment of the invention will now be described with reference to the following examples:

#### Example 1

25 A polyethylene glycol with a weight average molecular weight of 8000 (PEG8000) is used to produce matrix substrate containing THPS, that has a melting point of approximately 50°C (suitable for storage in most areas of the world) and readily dissolving within 5 minutes in water at 20°C.

30 Example 2

As shown in Table 1 below, THPS, embedded within a PEG8000 matrix, can be deployed in the presence of an oxygen scavenger without hindering the deaeration process. Experiment three shows complete deaeration within 15 seconds when an embedded biocide in accordance with the present invention is used, compared with no deaeration when a liquid biocide is used (Experiment 2).

### Example 3

The THPS/PEG8000 candle described above was tested in a standard quantitative suspension test to measure the antimicrobial activity of the embedded biocide. Such tests involve the addition of the biocide to the system water for a specified contact period, deactivation of the biocide after the specified contact period and subsequent enumeration of the remaining viable bacteria using Most Probable Number (MPN) techniques widely known within the industry.

From the graph below (Graph 1) it can be seen that THPS embedded in a PEG8000 matrix substrate (Tolcide® candle H2) has no adverse effects upon the antimicrobial performance of THPS when compared with liquid THPS (Tolcide® PS75).

The control shows the viability of the bacteria when not exposed to THPS.

EXP	Description	Oxygen Scavenging Y/N	Time to reach zero O <sub>2</sub>	Comments
1	500 ppm erythorbic acid (oxygen scavenger) in water :using 15ppm catalyst-CuSO <sub>4</sub>	Y	15 seconds	This confirms the deaeration efficacy of erythorbic acid-
2	Repeat of experiment 1 but 450ppm THPS was introduced via a conventional liquid product	N	Virtual ly no deaeration occurred even after 15 minutes )	
3	Repeat of experiment 1 but 450 ppm THPS, encapsulated within a PEG8000 candle, was introduced .	Y	15 seconds	Solid dissolved in ~5 min

Table 1

## CLAIMS

1. A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris (hydroxyorgano) phosphine (THP), a THP<sup>+</sup> salt (tetrakis (hydroxyorgano) phosphonium salt) or a condensate of THP and a nitrogen containing compound.  
5
2. A phosphonium compound as claimed in claim 1, in which the THP<sup>+</sup> salt is tetrakis (hydroxymethyl) phosphonium sulphate.  
10
3. A phosphonium compound as claimed in claim 1, in which the THP salt is selected from the group consisting of tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium formate, tetrakis (hydroxymethyl) phosphonium acetate and tetrakis (hydroxymethyl) phosphonium oxalate.  
15
4. A phosphonium compound as claimed in any preceding claim, in which the nitrogen containing compound is urea.  
20
5. A phosphonium compound as claimed in any one of claims 1 to 3, in which the nitrogen containing compound is melamine, guanidine or dicyandiamide.
- 25 6. A phosphonium compound as claimed in anyone of the preceding claims, in which the matrix substrate has a melting point of between 5 to 80° C.
7. A phosphonium compound as claimed in claim 6, in which the matrix substrate has a melting point of between 20 to 70° C.  
30

8. A phosphonium compound as claimed in claim 7, in which the matrix substrate has a melting point of 60° C.
9. A phosphonium compound as claimed in anyone of the preceding  
5 claims, in which the matrix substrate is soluble in water at a temperature of between 5 to 100° C.
10. A phosphonium compound as claimed in claim 9, in which the matrix substrate is soluble in water at a temperature of 20° C.
- 10 11. A phosphonium compound as claimed in anyone of the preceding claims in which the matrix substrate is selected from a polyhydric compound.
- 15 12. A phosphonium compound as claimed in claim 11, in which the polyhydric compound is a polyethylene glycol with a molecular weight of above 600.
- 20 13. A phosphonium compound as claimed in claim 11, in which the polyhydric compound is polyethylene glycol 8000.
- 25 14. A phosphonium compound as claimed in anyone of claims 1 to 10 in which the matrix substrate is selected from a group consisting of ethoxylated surfactants, fatty alcohols, ethoxylated fatty alcohols, ethoxylated alkyl phenols, ethoxylated fatty acids, fatty acid alkanolamides, ethylene oxide/propylene oxide block copolymers, ethoxylated/propoxylated fatty alcohols, polyethylene glycol esters, glycol esters, alkyl benzene sulphonic acids and salts thereof.

15. A phosphonium compound as claimed in any one of the preceding claims, wherein the matrix substrate is a mixture of two or more of the polyhydric compound defined in any one of claims 12 to 14.

5 16. The use of a phosphonium compound as defined in claims 1 to 15.

17. The use of a phosphonium compound as claimed in any one of claims 1 to 15 to reduce the numbers of micro-organisms in industrial systems.

10

18. The use of phosphonium compound as claimed in claim 17 in which the industrial system is selected from the group consisting of storage vessels for water and fuel; fuel and gas pipelines; gas lift wells; water injection systems; oil or gas production wells; cooling tower aqueous  
15 systems; aqueous systems in paper reduction and the like and any other aqueous systems where micro-organism contamination is a problem.

19. The use of phosphonium compound as claimed in claim 17 or claim 18, in which the micro-organism is selected from the group consisting of  
20 sulphate reducing bacteria, general heterotrophic bacteria and algae.

20. The use of phosphonium compound as claimed in any one of claims 1 to 15 to reduce iron carbonate or iron, lead and zinc scale deposits.

25 21. A method for reducing the numbers of micro-organisms in an industrial system which method comprises a step of contacting the industrial system with an effective amount of phosphonium compound as defined in anyone of claims 1 to 15 to reduce the number of micro-organisms.

30

22. A method for reducing the amount of scale in an industrial system which method comprises the step of contacting the industrial system with an effective amount of a phosphonium compound defined in anyone of claims 1 to 15 to reduce the amount of scale.

5

23. A phosphonium compound as claimed in any one of claims 1 to 15, in which said compound is formulated with one or more of the following: scale inhibitors, corrosion inhibitors, additional biocides, demulsifiers, gas hydrate inhibitors, asphaltene inhibitors/dispersants, other  
10 surfactants, anti-foams/defoamers, fragrances, wax inhibitors, scale dissolvers, gelling agents, oxygen scavengers.

24. A phosphonium compound as claimed in any one of claims 1 to 15, in which said compound is in the form of sticks/candles, beads, pellets,  
15 bricks, shavings, flakes or prills.

25. A phosphonium compound substantially as described herein with reference to the examples.

20 26. The use of a phosphonium compound substantially as described herein.


27. A method for reducing the numbers of micro-organisms in an industrial system substantially as described herein.

25

28. A method for reducing the amount of scale in an industrial system substantially described herein.







5

Graph 1

10

15

